Fluxion | GenomeWeb

Fluxion

Both institutions aim to develop novel liquid biopsy approaches that would improve physicians' ability to diagnose, monitor, and treat cancer patients. 

The jointly developed workflow uses Fluxion's IsoFlux system for circulating tumor cell enrichment along with Swift's Accel-Amplicon technology.

NEW YORK (GenomeWeb) – Fluxion Biosciences said today that it will collaborate with the Stanford University School of Medicine on developing molecular diagnostic tests to identify circulating tumor cells.

NEW YORK (GenomeWeb News) – Bulldog Bio today said it will distribute Fluxion Biosciences' flow cell instruments to research laboratories in North America.

NEW YORK (GenomeWeb News) – Molecular Devices today announced a global distribution agreement with Fluxion Biosciences covering its IonFlux instruments and consumables.
Molecular Devices also is providing support for all IonFlux Systems users as part of the deal, it said.

NEW YORK (GenomeWeb News) – Fluxion Biosciences said today it has registered its South San Francisco, Calif., facility as a medical device facility with the US Food and Drug Administration.

NEW YORK (GenomeWeb News) – Cellectricon and Fluxion Biosciences announced today they have settled a legal dispute dating back to 2009 in which Fluxion was accused of patent infringement.

NEW YORK (GenomeWeb News) – Fluxion Biosciences said today it is collaborating with the Stanford University School of Medicine to develop tests to help tailor treatments for cancer patients.

NEW YORK (GenomeWeb News) – Fluxion Biosciences today said that it has signed a reagent supply and collaboration agreement with Rubicon Genomics aimed at circulating tumor cell applications.

NEW YORK (GenomeWeb News) – Transgenomic said in a document filed with the US Securities and Exchange Commission this week that its shareholders have approved an increase in the number of authorized shares of the firm's common stock from 100 million to 150 million.

Pages

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.